DragonFLY
Pharmaceutical compound
From Wikipedia, the free encyclopedia
DragonFLY, also known as DFLY or H-DFLY, is a serotonin receptor agonist of the phenethylamine, DOx, and FLY families.[1][2] It is the "dragonFLY" (benzodifuran) analogue of 2,5-dimethoxyamphetamine (2,5-DMA or DOH).[1][2]
- None
 | |
| Clinical data | |
|---|---|
| Other names | DFLY; H-DFLY |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H13NO2 |
| Molar mass | 215.252 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
The enantiomers of DFLY, (R)-DFLY and (S)-DFLY, show affinity and activity at the serotonin 5-HT2 receptors.[1][2] At the serotonin 5-HT2A receptor, the affinity (Ki) of (R)-DFLY was 1.5 nM and of (S)-DFLY was 37.9 nM, while at the serotonin 5-HT2C receptor, the affinity (Ki) of (R)-DFLY was 0.79 nM and of (S)-DFLY was 6.0 nM.[2] In terms of activational potency at the serotonin 5-HT2A receptor, the EC50 (Emax) of (R)-DFLY was 590 nM (76%) while that of (S)-DFLY was 650 nM (68%).[2] The enantiomers of DFLY have far greater activity as serotonin 5-HT2A receptor agonists than (R)-2,5-DMA but show dramatically lower potency than 4-substituted FLY analogues like Bromo-DragonFLY.[2]
DFLY was included and described as an entry in Alexander Shulgin's 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds.[1] However, it is not known to have been assessed in animals or humans, and hence it is unknown whether DFLY has psychedelic or other psychoactive effects in humans.[1]
History
DFLY was first described in the scientific literature by at least 1999.[1][2][3] It was not an explicitly controlled substance in the United States as of 2011.[1]
Society and culture
Legal status
Canada
DragonFLY is a controlled substance in Canada under phenethylamine blanket-ban language.[4]